# Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant

> **NCT04836390** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Michael Pulsipher** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions

## Key facts

- **NCT ID:** NCT04836390
- **Lead sponsor:** Michael Pulsipher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-08-24
- **Primary completion:** 2026-05
- **Final completion:** 2028-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836390, "Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04836390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*